HER2 Antibodies Market: By Drug Type (Pertuzumab, Trastuzumab, Ado-trastuzumab, emtansine, Lapatinib, Everolimus), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography.  

Purchase Option

$ 4400
$ 6600
$ 8900

HER2 antibodies market Size was valued at US$ 10.6 Bn in 2022, growing at a significant CAGR of 8.6% over the forecast period 2023 to 2029. HER2 antibodies are the products used in the treatment of HER2 positive breast cancer HER2 is the member of human epidermal growth factor family. Over-expression of HER2 oncogene leads to development and progression of certain types of aggressive breast cancer. Rise in incidence of HER2 positive breast cancer around the globe, rise in R&D for the innovation of newer drugs for HER2 positive breast cancer treatment, promising pipeline products for the treatment, government initiations for breast cancer awareness among the masses, and advanced techniques for HER2 positive breast cancer diagnosis are expected to upsurge the revenue of global HER2 antibodies market over the forecast years. However, high cost of drugs, adverse effects associated with drugs, and fewer produts availability in the market may restrain the growth of global HER2 antibodies market. The HER protein and growth factor family is made up of four members, each with its own set of functions. Herceptin (Trastuzumab) binds to HER-two (HER-alphaextracellular )'s domain, preventing it from attaching to other receptors including insulin-like growth factor receptors (IGF/IR). Trastuzumab was first developed in 1998 for the treatment of metastatic breast cancer, but it has since been discovered to have other applications. 

Her2 Antibodies Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.6%

Largest Market

North America

Fastest Growing Market

Europe
HER2 Antibodies Market Dynamics

The protein on the cell surface that helps the cell develop is controlled by the human epidermal growth factor receptor 2 (HER2). It is a member of the epidermal growth factor receptor family. It's a tyrosine kinase receptor with a transmembrane structure. The expansion of the tumour is caused by alterations in HER2. When the HER2 gene is expressed in more than two cells, an excessive amount of HER2 protein is produced, which is known as overexpression of HER2. HER2 expression has been found on epithelial cell membranes in the gastrointestinal tract, skin, breast, urinary tract, placenta, skeleton muscle cells, and the heart. HER2 expression is generally higher in fatal tissue than in normal adult tissue. Overexpression of the HER2 protein causes HER2 breast cancer, which is one of the most dangerous kinds of breast cancer.

Her2 Antibodies Market Segmentation

By Drug Type
  • Pertuzumab
  • Trastuzumab
  • Ado-trastuzumab emtansine
  • Lapatinib
  • Everolimus
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Geography
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

Frequently Asked Questions

The HER2 Antibodies Market is studied from 2023 - 2029.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

 

1.Executive Summary
2.Global HER2 Antibodies Market Introduction 
2.1.Global HER2 Antibodies Market  - Taxonomy
2.2.Global HER2 Antibodies Market  - Definitions
2.2.1.Drug Type
2.2.2.Distribution Channel
2.2.3.Region
3.Global HER2 Antibodies Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global HER2 Antibodies Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global HER2 Antibodies Market  By Drug Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Pertuzumab
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Trastuzumab
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Ado-trastuzumab emtansine
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Lapatinib
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Everolimus
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6.Global HER2 Antibodies Market  By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Online Pharmacies
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global HER2 Antibodies Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Middle East and Africa (MEA)
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Latin America
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.North America HER2 Antibodies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.Pertuzumab
8.1.2.Trastuzumab
8.1.3.Ado-trastuzumab emtansine
8.1.4.Lapatinib
8.1.5.Everolimus
8.2.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Hospital Pharmacies
8.2.2.Retail Pharmacies
8.2.3.Online Pharmacies
8.3.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe HER2 Antibodies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Pertuzumab
9.1.2.Trastuzumab
9.1.3.Ado-trastuzumab emtansine
9.1.4.Lapatinib
9.1.5.Everolimus
9.2.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Hospital Pharmacies
9.2.2.Retail Pharmacies
9.2.3.Online Pharmacies
9.3.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10.Asia Pacific (APAC) HER2 Antibodies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Pertuzumab
10.1.2.Trastuzumab
10.1.3.Ado-trastuzumab emtansine
10.1.4.Lapatinib
10.1.5.Everolimus
10.2.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Hospital Pharmacies
10.2.2.Retail Pharmacies
10.2.3.Online Pharmacies
10.3.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Middle East and Africa (MEA) HER2 Antibodies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Pertuzumab
11.1.2.Trastuzumab
11.1.3.Ado-trastuzumab emtansine
11.1.4.Lapatinib
11.1.5.Everolimus
11.2.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Hospital Pharmacies
11.2.2.Retail Pharmacies
11.2.3.Online Pharmacies
11.3.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.GCC Countries
11.3.2.South Africa
11.3.3.Rest of MEA
12.Latin America HER2 Antibodies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Drug Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Pertuzumab
12.1.2.Trastuzumab
12.1.3.Ado-trastuzumab emtansine
12.1.4.Lapatinib
12.1.5.Everolimus
12.2.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Hospital Pharmacies
12.2.2.Retail Pharmacies
12.2.3.Online Pharmacies
12.3.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Brazil
12.3.2.Mexico
12.3.3.Rest of LA
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.Novartis AG (Switzerland)
13.2.2.Pfizer Inc. (U.S.)
13.2.3.Biocon Limited (India)
13.2.4.Abnova Corporation (Taiwan)
13.2.5.Genentech Inc. (U.S.)
13.2.6.InvivoGen (U.S.)
13.2.7.Bio-Techne Corporation (U.S.)
13.2.8.Celltrion Healthcare (South Korea)
13.2.9.Puma Biotechnology (U.S.)
14. Research Methodology 
15. Appendix and Abbreviations 
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Biocon Limited (India)
  • Abnova Corporation (Taiwan)
  • Genentech Inc. (U.S.)
  • InvivoGen (U.S.)
  • Bio-Techne Corporation (U.S.)
  • Celltrion Healthcare (South Korea)
  • Puma Biotechnology (U.S.)

Adjacent Markets